← Leaderboards

Steven Grant Deeks

University Of California Los Angeles

Google Scholar ↗PubMed ↗ORCID ↗

$52,964,444

Attributed

$86,809,888

Total exposure

25

Grants

12

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $10.3M · FY2005–25

$20M$15M$10M$5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$116,308,858 · 26

By mechanism

UM1$54,898,020 · 2

U19$38,507,365 · 4

U01$10,122,508 · 2

P30$3,724,563 · 3

R01$3,624,082 · 2

P01$2,429,154 · 1

Top collaborators

Most similar at University Of California Los Angeles

Same institution · by research overlap

William E Cunningham$11,274,835
Ian Michael McGowan$58,156,521

Others in their field

Top investigators on “Hiv Infections”

Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
Judith S. Currier · University Of California Los Angeles$466,447,923
Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678

Research focus

Hiv InfectionsClinical ResearchViralBaseCellsAntiretroviral TherapyVirusInfectionProgramsT-LymphocytePreventHuman SubjectHuman Therapy EvaluationAcquired Immunodeficiency SyndromeLifeCohortAids TherapyAnti-Retroviral AgentsDesignRegimenPharmaceutical PreparationsResearch PersonnelClinical TrialsIn Vivo

Grant awards (98)

Delaney AIDS Research Enterprise to Cure HIV$4,998,394

UM1 · FY2025 · AI · contact PI

A Phase 1/2a, randomized study of a Tfh-targeting genetic vaccine adjuvant designed to induce broad, durable immune responses$1,417,453

U01 · FY2025 · AI

Clinical Core$449,477

P30 · FY2025 · AI · contact PI

Delaney AIDS Research Enterprise to Cure HIV$5,455,521

UM1 · FY2024 · AI · contact PI

A Phase 1/2a, randomized study of a Tfh-targeting genetic vaccine adjuvant designed to induce broad, durable immune responses$1,435,214

U01 · FY2024 · AI

Clinical Core$628,667

P30 · FY2024 · AI · contact PI

Delaney AIDS Research Enterprise to Cure HIV$5,452,430

UM1 · FY2023 · AI · contact PI

Clinical Core$768,945

P30 · FY2023 · AI · contact PI

Delaney AIDS Research Enterprise to Cure HIV$5,448,894

UM1 · FY2022 · AI · contact PI

Clinical Core$728,162

P30 · FY2022 · AI · contact PI

Delaney AIDS Research Enterprise to Cure HIV$5,612,699

UM1 · FY2021 · AI · contact PI

Therapeutic vaccination and PD-1 blockade in treated HIV disease$1,336,452

U01 · FY2021 · AI · contact PI

Delaney AIDS Research Enterprise to Cure HIV$5,544,984

UM1 · FY2020 · AI · contact PI

Therapeutic vaccination and PD-1 blockade in treated HIV disease$1,377,326

U01 · FY2020 · AI · contact PI

Delaney AIDS Research Enterprise to Cure HIV$5,797,109

UM1 · FY2019 · AI · contact PI

Therapeutic vaccination and PD-1 blockade in treated HIV disease$1,693,836

U01 · FY2019 · AI · contact PI

Delaney AIDS Research Enterprise to Cure HIV$5,547,114

UM1 · FY2018 · AI · contact PI

Therapeutic vaccination and PD-1 blockade in treated HIV disease$1,370,393

U01 · FY2018 · AI · contact PI

Delaney AIDS Research Enterprise to Cure HIV$5,493,761

UM1 · FY2017 · AI · contact PI

Therapeutic vaccination and PD-1 blockade in treated HIV disease$1,491,834

U01 · FY2017 · AI · contact PI

Delaney AIDS Research Enterprise to Cure HIV$5,547,114

UM1 · FY2016 · AI · contact PI

Impact of HIV-associated inflammation on disease$109,836

K24 · FY2016 · AI · contact PI

DARE: Delaney AIDS Research Enterprise to find a cure.$5,807,143

U19 · FY2015 · AI · contact PI

Myeloid - T cell interactions that sustain SIV reservoirs during effective antire$1,005,145

U19 · FY2015 · AI · contact PI

Reversal of HIV latency in vivo$664,411

U19 · FY2015 · AI · contact PI

Administrative$318,016

U19 · FY2015 · AI · contact PI

Impact of HIV-associated inflammation on disease$111,626

K24 · FY2015 · AI · contact PI

DARE: Delaney AIDS Research Enterprise to find a cure.$7,309,244

U19 · FY2014 · AI · contact PI

Myeloid - T cell interactions that sustain SIV reservoirs during effective antire$1,678,316

U19 · FY2014 · AI · contact PI

Reversal of HIV latency in vivo$978,330

U19 · FY2014 · AI · contact PI

Administrative$229,527

U19 · FY2014 · AI · contact PI

Impact of HIV-associated inflammation on disease$113,346

K24 · FY2014 · AI · contact PI

DARE: Delaney AIDS Research Enterprise to find a cure.$5,568,822

U19 · FY2013 · AI · contact PI

Myeloid - T cell interactions that sustain SIV reservoirs during effective antire$882,883

U19 · FY2013 · AI · contact PI

Clinical and Population Sciences$767,901

P30 · FY2013 · AI · contact PI

Administrative$257,999

U19 · FY2013 · AI · contact PI

Impact of HIV-associated inflammation on disease$114,999

K24 · FY2013 · AI · contact PI

DARE: Delaney AIDS Research Enterprise to find a cure.$6,511,956

U19 · FY2012 · AI · contact PI

Myeloid - T cell interactions that sustain SIV reservoirs during effective antire$1,116,751

U19 · FY2012 · AI · contact PI

Reversal of HIV latency in vivo$740,374

U19 · FY2012 · AI · contact PI

Clinical and Population Sciences$381,411

P30 · FY2012 · AI · contact PI

Administrative$219,922

U19 · FY2012 · AI · contact PI

Impact of HIV-associated inflammation on disease$116,589

K24 · FY2012 · AI · contact PI

DARE: Delaney AIDS Research Enterprise to find a cure.$4,301,805

U19 · FY2011 · AI · contact PI

Evolution of HIV Envelope Following HIV Transmission$531,338

P01 · FY2011 · AI · contact PI

Reversal of HIV latency in vivo$395,132

U19 · FY2011 · AI · contact PI

Myeloid - T cell interactions that sustain SIV reservoirs during effective antire$320,029

U19 · FY2011 · AI · contact PI

Administrative$201,560

U19 · FY2011 · AI · contact PI

Preventing the Establishment of Enfuvirtide-resistance in the Latent Reservoir$191,048

K24 · FY2011 · AI · contact PI

The impact of early antiretroviral therapy on HIV persistence and inflammation$685,462

R01 · FY2010 · AI · contact PI

Evolution of HIV Envelope Following HIV Transmission$594,451

P01 · FY2010 · AI · contact PI

Preventing the Establishment of Enfuvirtide-resistance in the Latent Reservoir$185,484

K24 · FY2010 · AI · contact PI

The impact of early antiretroviral therapy on HIV persistence and inflammation$183,177

R01 · FY2010 · AI · contact PI

The impact of early antiretroviral therapy on HIV persistence and inflammation$723,144

R01 · FY2009 · AI · contact PI

Evolution of HIV Envelope Following HIV Transmission$475,718

P01 · FY2009 · AI · contact PI

Preventing the Establishment of Enfuvirtide-resistance in the Latent Reservoir$180,081

K24 · FY2009 · AI · contact PI

Evolution of HIV Envelope Following HIV Transmission$439,330

P01 · FY2008 · AI · contact PI

Preventing the Establishment of Enfuvirtide-resistance in the Latent Reservoir$174,836

K24 · FY2008 · AI · contact PI

Evolution of HIV Envelope Following HIV Transmission$388,317

P01 · FY2007 · AI · contact PI

Preventing the Establishment of Enfuvirtide-resistance in the Latent Reservoir$169,744

K24 · FY2007 · AI · contact PI

Immunologic Control of Drug-resistant HIV-1$502,556

R01 · FY2005 · AI

STUDY OF THE CONSEQUENCES OF PROTEASE INHIBITOR ERA$211,495

M01 · FY2005 · RR

TREATMENT INTERRUPTION WITH MULTI-DRUG RESISTANT HIV$204,673

M01 · FY2005 · RR

TREATMENT INTENSIFICATION AND DE-INTENSIFICATION IN HIV-1 PATIENTS$135,691

M01 · FY2005 · RR

HIV+ ADULTS WITH LOW DETECTABLE VIRAL LOADS ON ANTIRETROVIRAL THERAPY$101,579

M01 · FY2005 · RR

Immunologic Control of Drug-resistant HIV-1$618,748

R01 · FY2004 · AI

Treatment interruption with multi-drug resistant HIV$279,033

M01 · FY2004 · RR

Treatment Intensification for Drug-Resistant HIV$227,250

R21 · FY2004 · AI

Study of the consequences of protease inhibitor era$95,738

M01 · FY2004 · RR

HIV+ ADULTS WITH LOW DETECTABLE VIRAL LOADS ON ANTIRETROVIRAL THERAPY$51,551

M01 · FY2004 · RR

Immunologic Control of Drug-resistant HIV-1$606,435

R01 · FY2003 · AI

Treatment Intensification for Drug-Resistant HIV$226,875

R21 · FY2003 · AI

Immunologic Control of Drug-resistant HIV-1$304,560

R01 · FY2002 · AI

SAFETY, TOLERANCE, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF PMPA IN HIV$0

M01 · FY2002 · RR

ANTIVIRAL ACTIVITY OF ORAL DAPD IN HIV-1 INFECTION$0

M01 · FY2002 · RR

ANTIVIRAL ACTIVITY OF ORAL DAPD IN HIV-1 INFECTION$0

M01 · FY2002 · RR

VIROLOGIC &IMMUNOLOGIC CONSEQUENCES OF PROTEASE INHIBITOR FAILURE$0

M01 · FY2002 · RR

VIROLOGIC &IMMUNOLOGIC CONSEQUENCES OF PROTEASE INHIBITOR FAILURE$0

M01 · FY2002 · RR

ABT 378 &RITONAVIR IN PROTEASE INHIBITOR EXPERIENCED HIV PATIENTS$0

M01 · FY2002 · RR

ABT 378 &RITONAVIR IN PROTEASE INHIBITOR EXPERIENCED HIV PATIENTS$0

M01 · FY2002 · RR

SAFETY, TOLERANCE, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF PMPA IN HIV$0

M01 · FY2002 · RR

ABT 378 &RITONAVIR IN PROTEASE INHIBITOR EXPERIENCED HIV PATIENTS$0

M01 · FY2001 · RR

ANTIVIRAL ACTIVITY OF ORAL DAPD IN HIV-1 INFECTION$0

M01 · FY2001 · RR

VIROLOGIC &IMMUNOLOGIC CONSEQUENCES OF PROTEASE INHIBITOR FAILURE$0

M01 · FY2001 · RR

SAFETY, TOLERANCE, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF PMPA IN HIV$0

M01 · FY2001 · RR

SAFETY, TOLERANCE, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF PMPA IN HIV$564

M01 · FY2000 · RR

ABT 378 &RITONAVIR IN PROTEASE INHIBITOR EXPERIENCED HIV PATIENTS$564

M01 · FY2000 · RR

AUTOLOGOUS CD4 ZETA GENE MODIFIED T CELLS IN HIV INFECTED PATIENTS$564

M01 · FY2000 · RR

ANTIVIRAL ACTIVITY OF ORAL DAPD IN HIV-1 INFECTION$0

M01 · FY2000 · RR

VIROLOGIC &IMMUNOLOGIC CONSEQUENCES OF PROTEASE INHIBITOR FAILURE$0

M01 · FY2000 · RR

VIROLOGIC &IMMUNOLOGIC CONSEQUENCES OF PROTEASE INHIBITOR FAILURE$0

M01 · FY2000 · RR

VIROLOGIC &IMMUNOLOGIC CONSEQUENCES OF PROTEASE INHIBITOR FAILURE$0

M01 · FY2000 · RR

SAFETY, TOLERANCE, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF PMPA IN HIV$0

M01 · FY2000 · RR

ABT 378 &RITONAVIR IN PROTEASE INHIBITOR EXPERIENCED HIV PATIENTS$0

M01 · FY2000 · RR

ABT 378 &RITONAVIR IN PROTEASE INHIBITOR EXPERIENCED HIV PATIENTS$0

M01 · FY2000 · RR

SAFETY, TOLERANCE, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF PMPA IN HIV$0

M01 · FY2000 · RR

ANTIVIRAL ACTIVITY OF ORAL DAPD IN HIV-1 INFECTION$0

M01 · FY2000 · RR

ANTIVIRAL ACTIVITY OF ORAL DAPD IN HIV-1 INFECTION$0

M01 · FY2000 · RR